Cargando…

Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging

The value of pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in distinguishing pituitary microadenoma subtypes was investigated in the present study. Pathology and follow-up outcomes were applied as the gold standard for differentiating between...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Jian, Zheng, Wenqiang, Zhang, Qin, Wu, Jiangfen, Zhang, Xuexi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444299/
https://www.ncbi.nlm.nih.gov/pubmed/30944618
http://dx.doi.org/10.3892/ol.2019.10083
_version_ 1783408007871201280
author Zhai, Jian
Zheng, Wenqiang
Zhang, Qin
Wu, Jiangfen
Zhang, Xuexi
author_facet Zhai, Jian
Zheng, Wenqiang
Zhang, Qin
Wu, Jiangfen
Zhang, Xuexi
author_sort Zhai, Jian
collection PubMed
description The value of pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in distinguishing pituitary microadenoma subtypes was investigated in the present study. Pathology and follow-up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin-producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone-producing tumors) and 20 patients with normal pituitary glands. DCE-MRI was conducted to obtain the following quantitative permeability parameters: Volume transfer constant (K(trans)), rate constant (K(ep)) and extracellular extravascular volume fraction (V(e)). Among the 76 cases included, 61 were visually diagnosed using conventional MRI. The K(trans), K(ep) and V(e) of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively. The K(trans), K(ep) and V(e) of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively. The K(trans) and K(ep) of patients with microadenomas were significantly lower compared with those of the normal controls (P<0.05). However, the V(e) of the two groups did not significantly differ. Subtype differentiation analysis revealed that patients with growth hormone-producing tumors exhibited the highest K(trans) value (P<0.05). K(ep) significantly differed between growth hormone-producing tumors and the other two subtypes (P<0.05), but did not significantly differ among three subtypes. Receiver-operator characteristic analysis indicated that the area under the curve values of K(trans) and K(ep) were 0.884 and 0.728, respectively. Sensitivity and specificity were 95.0 and 82.6%, respectively, when K(trans) was set to 0.614/min as the cut-off value, and when the K(ep) cut-off value was set to 0.985/min, sensitivity and specificity were 60.0 and 81.3%, respectively. In conclusion, K(trans) and K(ep) derived from DCE-MRI could be applied to detect and identify microadenoma subtypes. K(trans) better reflects the blood perfusion alterations exhibited by patients with different microadenoma subtypes.
format Online
Article
Text
id pubmed-6444299
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-64442992019-04-03 Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging Zhai, Jian Zheng, Wenqiang Zhang, Qin Wu, Jiangfen Zhang, Xuexi Oncol Lett Articles The value of pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in distinguishing pituitary microadenoma subtypes was investigated in the present study. Pathology and follow-up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin-producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone-producing tumors) and 20 patients with normal pituitary glands. DCE-MRI was conducted to obtain the following quantitative permeability parameters: Volume transfer constant (K(trans)), rate constant (K(ep)) and extracellular extravascular volume fraction (V(e)). Among the 76 cases included, 61 were visually diagnosed using conventional MRI. The K(trans), K(ep) and V(e) of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively. The K(trans), K(ep) and V(e) of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively. The K(trans) and K(ep) of patients with microadenomas were significantly lower compared with those of the normal controls (P<0.05). However, the V(e) of the two groups did not significantly differ. Subtype differentiation analysis revealed that patients with growth hormone-producing tumors exhibited the highest K(trans) value (P<0.05). K(ep) significantly differed between growth hormone-producing tumors and the other two subtypes (P<0.05), but did not significantly differ among three subtypes. Receiver-operator characteristic analysis indicated that the area under the curve values of K(trans) and K(ep) were 0.884 and 0.728, respectively. Sensitivity and specificity were 95.0 and 82.6%, respectively, when K(trans) was set to 0.614/min as the cut-off value, and when the K(ep) cut-off value was set to 0.985/min, sensitivity and specificity were 60.0 and 81.3%, respectively. In conclusion, K(trans) and K(ep) derived from DCE-MRI could be applied to detect and identify microadenoma subtypes. K(trans) better reflects the blood perfusion alterations exhibited by patients with different microadenoma subtypes. D.A. Spandidos 2019-05 2019-02-28 /pmc/articles/PMC6444299/ /pubmed/30944618 http://dx.doi.org/10.3892/ol.2019.10083 Text en Copyright: © Zhai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhai, Jian
Zheng, Wenqiang
Zhang, Qin
Wu, Jiangfen
Zhang, Xuexi
Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title_full Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title_fullStr Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title_full_unstemmed Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title_short Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
title_sort pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444299/
https://www.ncbi.nlm.nih.gov/pubmed/30944618
http://dx.doi.org/10.3892/ol.2019.10083
work_keys_str_mv AT zhaijian pharmacokineticanalysisforthedifferentiationofpituitarymicroadenomasubtypesthroughdynamiccontrastenhancedmagneticresonanceimaging
AT zhengwenqiang pharmacokineticanalysisforthedifferentiationofpituitarymicroadenomasubtypesthroughdynamiccontrastenhancedmagneticresonanceimaging
AT zhangqin pharmacokineticanalysisforthedifferentiationofpituitarymicroadenomasubtypesthroughdynamiccontrastenhancedmagneticresonanceimaging
AT wujiangfen pharmacokineticanalysisforthedifferentiationofpituitarymicroadenomasubtypesthroughdynamiccontrastenhancedmagneticresonanceimaging
AT zhangxuexi pharmacokineticanalysisforthedifferentiationofpituitarymicroadenomasubtypesthroughdynamiccontrastenhancedmagneticresonanceimaging